Recent studies have demonstrated that p38-MAPK signaling [6], PI3K/AKT signaling [7] and NF-κB signaling [8] are activated in HCC cells and during the acquisition of sorafenib resistance. This evidence concerns the gene NFKB1 and hepatocellular carcinoma.